The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
SIG – EAHP guidance on the pharmacy handling of in vivo gene therapy medicinal products
Affiliation
Pediatric Cancer Center Barcelona - Sant Joan de Déu Hospital
Country
Spain
Current position
Joan Vinent is currently the head of the pediatric cancer pharmacy services of the Pediatric Cancer Center Barcelona (PCCB) as part of Hospital Sant Joan de Déu (SJD) Hospital. I am a consultant practitioner in pediatric haematology and solid tumour, BMT and advanced therapies. I am professionally and managerially responsible for the provision of pharmaceutical care to cancer services at the PCCB. I have overall responsibility for the safe and efficient provision of different anticancer therapies including cytotoxic chemotherapy, small molecule targeted therapies, monoclonal antibodies and ATMPs. I also contribute to policy and strategy development of pharmacy services at SJD Hospital.
Education
Joan Vinent studied Pharmacy at the University of Barcelona (UB) and became licensed pharmacist in 1997. In 2002, he completed the residency program at Bellvitge University Hospital (Barcelona) and became specialist hospital pharmacy. He holds a Master’s Degree in Research and Development of Medicines (UB), a Diploma in Statistic in Human Sciences (Autonomous University of Barcelona) and several postgraduate courses. Joan has developed his professional career in different comprehensive cancer centers including the Catalan Institute for Oncology and Oxford University Hospitals before his current position. He Joan is board certified oncology pharmacy (BCOP) since 2005 and board certified pediatric pharmacist (BCPPS) since 2017 in the US.
Research area
Joan Vinent research focuses on pediatric oncology investigational drugs, ATMPs and therapeutic drug monitoring. He has participated as co-investigator in several academic clinical trials with competitive funding. He also has operational experience in all developmental phases of IP from clinical research to market access. He is member of the expert committee of the Spanish Ministry of Health for the evaluation of CART cell treatments.
Conflict of interest
None